Rapport Therapeutics, Inc. Common Stock (RAPP) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Rapport Therapeutics, Inc. Common Stock, with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Valuation | ||||
| P/E Ratio | -12.79x | -4.70x | -10.81x | -39.28x |
| P/B Ratio | 2.94x | 1.20x | -14.67x | 21.45x |
| P/S Ratio | 0.00x | 0.00x | 0.00x | 0.00x |
| Profitability | ||||
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| EBITDA Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| Liquidity | ||||
| Current Ratio | 26.17x | 35.34x | 17.14x | 18.80x |
| Quick Ratio | 26.17x | 35.34x | 17.14x | 18.80x |
| Leverage | ||||
| Debt/Equity | 0.02x | 0.00x | -0.08x | 0.53x |
YoY = year-over-year change. Source: FMP..